Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Han Noll

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Seminars in Immunology|September 20, 2023
Beyond youth: Understanding CAR T cell fitness in the context of immunological agingJulia Han Noll, Bruce L Levine, Carl H June, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Extramedullary Multiple Myeloma: Challenges and OpportunitiesMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Molecular Therapy. Oncology|July 11, 2026
CART-immune-related adverse events after BCMA CAR-T therapyLuca Paruzzo, Matthew Ho, Julia Han Noll, et al.
Nature Communications|May 3, 2020
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapyDaniel Baumann, Tanja Hägele, Julian Mochayedi, et al.
JCI Insight|May 10, 2022
A phase I trial of cyclosporine for hospitalized patients with COVID-19Emily A Blumberg, Julia Han Noll, Pablo Tebas, et al.
Nature Communications|May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.
The New England Journal of Medicine|May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous FailureJakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Seminars in Immunology|September 20, 2023
Beyond youth: Understanding CAR T cell fitness in the context of immunological agingJulia Han Noll, Bruce L Levine, Carl H June, et al.
Current Oncology (Toronto, Ont.)|March 26, 2025
Extramedullary Multiple Myeloma: Challenges and OpportunitiesMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Molecular Therapy. Oncology|July 11, 2026
CART-immune-related adverse events after BCMA CAR-T therapyLuca Paruzzo, Matthew Ho, Julia Han Noll, et al.
Nature Communications|May 3, 2020
Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapyDaniel Baumann, Tanja Hägele, Julian Mochayedi, et al.
JCI Insight|May 10, 2022
A phase I trial of cyclosporine for hospitalized patients with COVID-19Emily A Blumberg, Julia Han Noll, Pablo Tebas, et al.
Nature Communications|May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.
The New England Journal of Medicine|May 7, 2025
Enhanced CAR T-Cell Therapy for Lymphoma after Previous FailureJakub Svoboda, Daniel J Landsburg, James Gerson, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Pageof 1